MONDAY, Aug. 31, 2020 (HealthDay News) — The Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology (MASCC/ISOO) have issued updated recommendations for the management of mucositis; a summary of these updates was published online July 28 in Cancer.

Sharon Elad, D.M.D., from the Eastman Institute for Oral Health at the University of Rochester Medical Center in New York, and colleagues conducted a systematic literature review to update the clinical practice guidelines for management of mucositis. Evidence from 1,197 publications relating to oral or gastrointestinal mucositis was reviewed.

The authors developed 13 new guidelines, which were categorized as recommendations, suggestions, or no guideline possible. With respect to basic oral care, multiagent combination oral care protocols were suggested as beneficial for prevention of oral mucositis (OM) during chemotherapy, head and neck radiotherapy (H&N RT), and hematopoietic stem cell transplantation (HSCT). Benzydamine mouthwash is recommended for prevention of OM in patients with H&N cancer receiving moderate-dose RT and is suggested for those receiving RT/chemotherapy. Intraoral photobiomodulation therapy using low-level laser therapy is recommended for prevention of OM in adults receiving HSCT conditioned with high-dose chemotherapy; intraoral therapy is recommended for adults receiving RT to the H&N. Oral cryotherapy is recommended for preventing OM in patients undergoing autologous HSCT when the conditioning includes high-dose melphalan. Honey is suggested for patients with H&N cancer receiving RT or RT/chemotherapy.

“Even with the best evidence-based interventions, we don’t have an ultimate guideline for mucositis in all clinical settings,” Elad said in a statement.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text

Copyright © 2020 HealthDay. All rights reserved.